US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Kyverna Therapeutics

7.68

-0.4200-5.19%

Post-market: 7.680.00000.00%19:23 EST

Volume:412.71K

Turnover:3.23M

Market Cap:438.75M

PE:-2.06

High:8.08

Open:8.00

Low:7.67

Close:8.10

52wk High:13.67

52wk Low:1.78

Shares:57.13M

Float Shares:33.30M

Volume Ratio:0.81

T/O Rate:1.24%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.7205

EPS(LYR):-3.3254

ROE:-70.82%

ROA:-40.75%

PB:2.89

PE(LYR):-2.31

Loading ...

Overview Company News Filings

Kyverna Therapeutics Files Initial Beneficial Ownership Statement for Chief Technology Officer Mayobanex Pujols

Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer

Kyverna Therapeutics Showcases Breakthrough CAR T Results in Autoimmune Diseases

Kyverna Therapeutics: Strong Early Autoimmune CAR-T Data, Accelerated SPS Timeline, and Solid Cash Runway Support Buy Rating

Kyverna Therapeutics provides corporate update, priorities for 2026

Kyverna Therapeutics Inc - Appoints Christi Shaw as Executive Chairperson - SEC Filing

THOMSON REUTERS

BRIEF-Kyverna Therapeutics Provides Corporate Update And Outlines 2026 Strategic Priorities At The J.P. Morgan Healthcare Conference

Kyverna Therapeutics Names Christi Shaw Executive Chairperson

Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference

Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference

Director Beth C. Seidenberg Acquires Common Shares of Kyverna Therapeutics Inc

Westlake BioPartners Opportunity Fund I, L.P. Reports Acquisition of Kyverna Therapeutics Common Shares

Kyverna Therapeutics Chief Technology Officer Karen Marie Walker Reports Disposal of Common Shares

Kyverna Therapeutics Down Over 29%, On Track for Largest Percent Decrease Since June 2024 -- Data Talk

BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Robinhood Markets, Cannabis stocks

Kyverna Therapeutics Inc - Underwriters Granted Option for 1,999,999 Additional Shares

THOMSON REUTERS

Kyverna Therapeutics Inc - Prices Public Offering of 13,333,333 Shares of Common Stock at $7.50 Each

THOMSON REUTERS

Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock

Investors Parse Jobs Data, Look Ahead to Inflation Report as US Futures Rise Pre-Bell

MT Newswires Live

Kyverna Therapeutics Is Maintained at Overweight by Wells Fargo

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/KYTX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"KYTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYTX\",,,,,undefined,":{"symbol":"KYTX","market":"US","secType":"STK","nameCN":"Kyverna Therapeutics","latestPrice":7.68,"timestamp":1771621200000,"preClose":8.1,"halted":0,"volume":412714,"hourTrading":{"tag":"盘后","latestPrice":7.68,"preClose":7.68,"latestTime":"19:23 EST","volume":10389,"amount":79785.02,"timestamp":1771633431349,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.05185185185185184,"floatShares":33297000,"shares":57129503,"eps":-3.72055,"marketStatus":"Market Closed","change":-0.42,"latestTime":"02-20 16:00:00 EST","open":8,"high":8.08,"low":7.67,"amount":3234572.099194,"amplitude":0.050617,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.72055,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"listingDate":1707368400000,"exchange":"NASDAQ","adjPreClose":8.1,"preHourTrading":{"tag":"盘前","latestPrice":8.05,"preClose":8.1,"latestTime":"09:24 EST","volume":920,"amount":7342.590104000001,"timestamp":1771597461170,"change":-0.05,"changeRate":-0.006173,"amplitude":0.020988},"postHourTrading":{"tag":"盘后","latestPrice":7.68,"preClose":7.68,"latestTime":"19:23 EST","volume":10389,"amount":79785.02,"timestamp":1771633431349,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8071301734333017,"impliedVol":1.0528,"impliedVolPercentile":0.2231},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYTX\",,,,,undefined,":{"symbol":"KYTX","floatShares":33297000,"roa":"-40.75%","roe":"-70.82%","lyrEps":-3.325379,"volumeRatio":0.8071301734333017,"shares":57129503,"dividePrice":0,"high":8.08,"amplitude":0.050617,"preClose":8.1,"low":7.67,"week52Low":1.78,"pbRate":"2.89","psRate":"1555.87","week52High":13.67,"institutionHeld":0,"latestPrice":7.68,"eps":-3.72055,"divideRate":0,"volume":412714,"delay":0,"ttmEps":-3.72055,"open":8,"prevYearClose":9.4,"prevWeekClose":7.26,"prevMonthClose":8.01,"prevQuarterClose":9.4,"fiveDayClose":7.36,"twentyDayClose":10.51,"sixtyDayClose":7.09},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KYTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-12","symbol":"KYTX","fiscalQuarterEnding":"2025/09","expectedEps":-0.97,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"post","actualEps":-0.85},{"market":"US","date":"2025-08-12","symbol":"KYTX","fiscalQuarterEnding":"2025/06","expectedEps":1,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-0.97},{"market":"US","date":"2025-05-13","symbol":"KYTX","fiscalQuarterEnding":"2025/03","expectedEps":-1.21,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"post","actualEps":-1.03},{"market":"US","date":"2025-03-27","symbol":"KYTX","fiscalQuarterEnding":"2024/12","expectedEps":-0.87,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"post","actualEps":-0.88},{"market":"US","date":"2024-11-13","symbol":"KYTX","fiscalQuarterEnding":"2024/09","expectedEps":-0.77,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-0.8}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KYTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KYTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1755666000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KYTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KYTX","date":"2026-02-20","current":-2.064211,"percent":0.396857,"low":-26.836094,"twenty":-4.986457,"median":-2.025703,"eighty":-1.014247,"high":-0.615209,"avg":-4.596975,"sd":6.321671,"marketCap":462748974},"quantilePoints":[{"date":"2024-02-09","current":-25.410847,"twenty":-24.055602,"median":-22.022734,"eighty":-19.989866,"marketCap":1224675750},{"date":"2024-02-16","current":-26.541682,"twenty":-26.641604,"median":-26.505996,"eighty":-25.427787,"marketCap":1279176368},{"date":"2024-02-23","current":-24.230994,"twenty":-26.541682,"median":-25.495549,"eighty":-24.578936,"marketCap":1167812779},{"date":"2024-03-01","current":-24.239916,"twenty":-26.505996,"median":-25.105309,"eighty":-24.54325,"marketCap":1168242754},{"date":"2024-03-08","current":-25.676289,"twenty":-26.318643,"median":-25.069622,"eighty":-24.578936,"marketCap":1237468769},{"date":"2024-03-15","current":-26.354329,"twenty":-26.354329,"median":-25.311608,"eighty":-24.712759,"marketCap":1270146888},{"date":"2024-03-22","current":-23.999034,"twenty":-26.354329,"median":-25.16776,"eighty":-24.239916,"marketCap":1156633422},{"date":"2024-03-28","current":-17.2201,"twenty":-26.32578,"median":-25.042858,"eighty":-23.820602,"marketCap":1039508532},{"date":"2024-04-05","current":-15.927342,"twenty":-26.311505,"median":-24.815357,"eighty":-20.313915,"marketCap":961469941},{"date":"2024-04-12","current":-17.062969,"twenty":-25.959995,"median":-24.578936,"eighty":-17.608641,"marketCap":1030023179},{"date":"2024-04-19","current":-13.577524,"twenty":-25.715544,"median":-24.235455,"eighty":-16.573007,"marketCap":819620788},{"date":"2024-04-26","current":-11.384836,"twenty":-25.597779,"median":-23.86521,"eighty":-16.071617,"marketCap":687256989},{"date":"2024-05-03","current":-10.734886,"twenty":-25.51207,"median":-23.093494,"eighty":-15.443094,"marketCap":648022117},{"date":"2024-05-10","current":-10.427767,"twenty":-25.427787,"median":-18.634621,"eighty":-13.461819,"marketCap":629482562},{"date":"2024-05-17","current":-8.660987,"twenty":-25.252064,"median":-17.663681,"eighty":-11.317698,"marketCap":657507471},{"date":"2024-05-24","current":-7.059414,"twenty":-25.176682,"median":-17.2201,"eighty":-10.732029,"marketCap":535922482},{"date":"2024-05-31","current":-7.116207,"twenty":-25.108877,"median":-16.627288,"eighty":-10.256351,"marketCap":540234007},{"date":"2024-06-07","current":-7.456968,"twenty":-25.053564,"median":-16.309455,"eighty":-9.030538,"marketCap":566103153},{"date":"2024-06-14","current":-5.412407,"twenty":-25.026799,"median":-16.020192,"eighty":-8.479248,"marketCap":410888275},{"date":"2024-06-21","current":-4.390126,"twenty":-24.958995,"median":-15.870204,"eighty":-7.953341,"marketCap":333280836},{"date":"2024-06-28","current":-4.259502,"twenty":-24.826956,"median":-14.259614,"eighty":-7.613717,"marketCap":323364330},{"date":"2024-07-05","current":-3.978375,"twenty":-24.748445,"median":-13.641804,"eighty":-7.429707,"marketCap":302022284},{"date":"2024-07-12","current":-5.56007,"twenty":-24.685994,"median":-12.649024,"eighty":-7.150283,"marketCap":422098238},{"date":"2024-07-19","current":-5.685015,"twenty":-24.571799,"median":-11.216991,"eighty":-6.028046,"marketCap":431583592},{"date":"2024-07-26","current":-5.588466,"twenty":-24.482583,"median":-10.813451,"eighty":-5.596417,"marketCap":424254000},{"date":"2024-08-02","current":-4.117518,"twenty":-24.238132,"median":-10.584898,"eighty":-5.421494,"marketCap":312585519},{"date":"2024-08-09","current":-3.725644,"twenty":-24.184602,"median":-9.999228,"eighty":-5.056881,"marketCap":282836000},{"date":"2024-08-16","current":-3.830678,"twenty":-23.972269,"median":-9.395703,"eighty":-4.700218,"marketCap":290809782},{"date":"2024-08-23","current":-4.597951,"twenty":-23.820602,"median":-8.80297,"eighty":-4.562778,"marketCap":349058032},{"date":"2024-08-30","current":-4.56385,"twenty":-23.561877,"median":-8.433813,"eighty":-4.558634,"marketCap":346469221},{"date":"2024-09-06","current":-4.171688,"twenty":-23.2407,"median":-8.189602,"eighty":-4.480996,"marketCap":316697893},{"date":"2024-09-13","current":-4.092119,"twenty":-22.946288,"median":-7.78069,"eighty":-4.395806,"marketCap":310657334},{"date":"2024-09-20","current":-3.631756,"twenty":-20.733738,"median":-7.624508,"eighty":-4.308092,"marketCap":275708384},{"date":"2024-09-27","current":-2.97247,"twenty":-18.634621,"median":-7.456968,"eighty":-4.211473,"marketCap":225658035},{"date":"2024-10-04","current":-2.63146,"twenty":-17.741488,"median":-7.394495,"eighty":-4.171688,"marketCap":199769924},{"date":"2024-10-11","current":-2.983837,"twenty":-17.707293,"median":-7.116207,"eighty":-4.052335,"marketCap":226520973},{"date":"2024-10-18","current":-3.205494,"twenty":-17.620069,"median":-6.641982,"eighty":-3.978375,"marketCap":243348245},{"date":"2024-10-25","current":-2.909952,"twenty":-17.56293,"median":-5.951944,"eighty":-3.964176,"marketCap":220911882},{"date":"2024-11-01","current":-2.779231,"twenty":-17.2201,"median":-5.608344,"eighty":-3.873307,"marketCap":210988106},{"date":"2024-11-08","current":-3.006571,"twenty":-17.062969,"median":-5.514635,"eighty":-3.751109,"marketCap":228246847},{"date":"2024-11-15","current":-1.697135,"twenty":-16.627288,"median":-5.392529,"eighty":-3.322005,"marketCap":187796512},{"date":"2024-11-22","current":-1.712741,"twenty":-16.355881,"median":-5.065967,"eighty":-3.177076,"marketCap":189523376},{"date":"2024-11-29","current":-2.251143,"twenty":-16.350167,"median":-4.969419,"eighty":-3.054313,"marketCap":249100201},{"date":"2024-12-06","current":-1.775165,"twenty":-16.285886,"median":-4.789428,"eighty":-3.003161,"marketCap":196430834},{"date":"2024-12-13","current":-1.724446,"twenty":-16.121613,"median":-4.674093,"eighty":-2.977017,"marketCap":190818525},{"date":"2024-12-20","current":-1.560584,"twenty":-16.033048,"median":-4.573541,"eighty":-2.950873,"marketCap":172686448},{"date":"2024-12-27","current":-1.556683,"twenty":-15.964482,"median":-4.562178,"eighty":-2.903132,"marketCap":172254731},{"date":"2025-01-03","current":-1.599599,"twenty":-15.904487,"median":-4.538274,"eighty":-2.797418,"marketCap":177003609},{"date":"2025-01-10","current":-1.346004,"twenty":-15.82735,"median":-4.480996,"eighty":-2.693979,"marketCap":148942061},{"date":"2025-01-17","current":-1.299186,"twenty":-15.443094,"median":-4.435561,"eighty":-2.615547,"marketCap":143761467},{"date":"2025-01-24","current":-1.404526,"twenty":-14.591731,"median":-4.395806,"eighty":-2.532048,"marketCap":155417803},{"date":"2025-01-31","current":-1.264073,"twenty":-13.927497,"median":-4.353211,"eighty":-2.095084,"marketCap":139876022},{"date":"2025-02-07","current":-1.170438,"twenty":-13.706085,"median":-4.259502,"eighty":-1.931223,"marketCap":129514836},{"date":"2025-02-14","current":-1.182143,"twenty":-13.577524,"median":-4.21845,"eighty":-1.814179,"marketCap":130809984},{"date":"2025-02-21","current":-1.084606,"twenty":-13.114702,"median":-4.187318,"eighty":-1.73693,"marketCap":120017081},{"date":"2025-02-28","current":-1.108015,"twenty":-12.719019,"median":-4.171688,"eighty":-1.688552,"marketCap":122607378},{"date":"2025-03-07","current":-1.01438,"twenty":-12.020501,"median":-4.104819,"eighty":-1.598038,"marketCap":112246191},{"date":"2025-03-14","current":-0.975365,"twenty":-11.480543,"median":-3.998252,"eighty":-1.555903,"marketCap":107929030},{"date":"2025-03-21","current":-0.928548,"twenty":-11.116285,"median":-3.978412,"eighty":-1.525471,"marketCap":102748436},{"date":"2025-03-28","current":-0.678003,"twenty":-10.923443,"median":-3.972766,"eighty":-1.481775,"marketCap":86429836},{"date":"2025-04-04","current":-0.671223,"twenty":-10.829164,"median":-3.959945,"eighty":-1.403746,"marketCap":85565537},{"date":"2025-04-11","current":-0.698343,"twenty":-10.750599,"median":-3.915931,"eighty":-1.33508,"marketCap":89022731},{"date":"2025-04-17","current":-0.630601,"twenty":-10.726315,"median":-3.836362,"eighty":-1.299186,"marketCap":80387103},{"date":"2025-04-25","current":-0.711969,"twenty":-10.557757,"median":-3.76816,"eighty":-1.283581,"marketCap":90759633},{"date":"2025-05-02","current":-0.772995,"twenty":-10.436338,"median":-3.711325,"eighty":-1.243785,"marketCap":98539030},{"date":"2025-05-09","current":-0.715359,"twenty":-10.170644,"median":-3.266591,"eighty":-1.184484,"marketCap":91191822},{"date":"2025-05-16","current":-0.68951,"twenty":-9.982087,"median":-3.188443,"eighty":-1.152492,"marketCap":100267785},{"date":"2025-05-23","current":-0.73409,"twenty":-9.837812,"median":-3.142975,"eighty":-1.119719,"marketCap":106750616},{"date":"2025-05-30","current":-0.781642,"twenty":-9.466412,"median":-3.049198,"eighty":-1.09553,"marketCap":113665635},{"date":"2025-06-06","current":-0.873775,"twenty":-9.030538,"median":-3.023622,"eighty":-1.030766,"marketCap":127063486},{"date":"2025-06-13","current":-1.02832,"twenty":-8.929052,"median":-2.986679,"eighty":-1.018767,"marketCap":149537300},{"date":"2025-06-20","current":-0.864859,"twenty":-8.793883,"median":-2.980995,"eighty":-1.008108,"marketCap":125766920},{"date":"2025-06-27","current":-1.031292,"twenty":-8.738225,"median":-2.966787,"eighty":-0.98785,"marketCap":149969489},{"date":"2025-07-03","current":-0.835139,"twenty":-8.660987,"median":-2.95542,"eighty":-0.975365,"marketCap":121445033},{"date":"2025-07-11","current":-1.061012,"twenty":-8.20664,"median":-2.912794,"eighty":-0.974824,"marketCap":154291376},{"date":"2025-07-18","current":-1.209614,"twenty":-8.200961,"median":-2.836066,"eighty":-0.975365,"marketCap":175900813},{"date":"2025-07-25","current":-1.260138,"twenty":-8.178243,"median":-2.779231,"eighty":-0.975365,"marketCap":183248021},{"date":"2025-08-01","current":-1.061012,"twenty":-7.803407,"median":-2.688295,"eighty":-0.975365,"marketCap":154291376},{"date":"2025-08-08","current":-0.98374,"twenty":-7.78069,"median":-2.625776,"eighty":-0.98374,"marketCap":143054469},{"date":"2025-08-15","current":-0.964666,"twenty":-7.68982,"median":-2.585992,"eighty":-0.974824,"marketCap":153089661},{"date":"2025-08-22","current":-0.975567,"twenty":-7.678462,"median":-2.530603,"eighty":-0.962936,"marketCap":154819487},{"date":"2025-08-29","current":-1.008267,"twenty":-7.570554,"median":-2.118493,"eighty":-0.964666,"marketCap":160008967},{"date":"2025-09-05","current":-0.989192,"twenty":-7.52512,"median":-1.993646,"eighty":-0.964666,"marketCap":156981771},{"date":"2025-09-12","current":-1.130894,"twenty":-7.468327,"median":-1.952681,"eighty":-0.972792,"marketCap":179469518},{"date":"2025-09-19","current":-1.365248,"twenty":-7.429707,"median":-1.872701,"eighty":-0.975257,"marketCap":216660791},{"date":"2025-09-26","current":-1.730404,"twenty":-7.422892,"median":-1.802474,"eighty":-0.975365,"marketCap":274609985},{"date":"2025-10-03","current":-1.656828,"twenty":-7.377457,"median":-1.775165,"eighty":-0.975365,"marketCap":262933655},{"date":"2025-10-10","current":-1.923883,"twenty":-7.30249,"median":-1.765048,"eighty":-0.975527,"marketCap":305314409},{"date":"2025-10-17","current":-1.910257,"twenty":-7.150283,"median":-1.79077,"eighty":-0.977747,"marketCap":303152125},{"date":"2025-10-24","current":-1.74403,"twenty":-7.070773,"median":-1.806706,"eighty":-0.98265,"marketCap":276772268},{"date":"2025-10-31","current":-1.839406,"twenty":-7.009436,"median":-1.817606,"eighty":-0.98374,"marketCap":291908252},{"date":"2025-11-07","current":-1.932058,"twenty":-6.429007,"median":-1.834596,"eighty":-0.986404,"marketCap":306611779},{"date":"2025-11-14","current":-1.76583,"twenty":-6.028046,"median":-1.829785,"eighty":-0.98707,"marketCap":280231922},{"date":"2025-11-21","current":-2.023973,"twenty":-5.954216,"median":-1.856881,"eighty":-0.988768,"marketCap":325843504},{"date":"2025-11-28","current":-2.086542,"twenty":-5.791787,"median":-1.873766,"eighty":-0.989487,"marketCap":335916623},{"date":"2025-12-05","current":-2.132789,"twenty":-5.650939,"median":-1.874832,"eighty":-0.990456,"marketCap":343361972},{"date":"2025-12-12","current":-2.27425,"twenty":-5.604368,"median":-1.895008,"eighty":-0.995653,"marketCap":366135981},{"date":"2025-12-19","current":-1.904276,"twenty":-5.571428,"median":-1.899357,"eighty":-1.000453,"marketCap":306573190},{"date":"2025-12-26","current":-2.445634,"twenty":-5.541896,"median":-1.907532,"eighty":-1.00316,"marketCap":393727568},{"date":"2026-01-02","current":-3.335677,"twenty":-5.503276,"median":-1.923883,"eighty":-1.005937,"marketCap":537017328},{"date":"2026-01-09","current":-2.998561,"twenty":-5.448754,"median":-1.93164,"eighty":-1.007666,"marketCap":482744300},{"date":"2026-01-16","current":-3.094373,"twenty":-5.404456,"median":-1.947802,"eighty":-1.008709,"marketCap":498169266},{"date":"2026-01-23","current":-3.729571,"twenty":-5.372651,"median":-1.953858,"eighty":-1.010478,"marketCap":600431076},{"date":"2026-01-30","current":-2.913395,"twenty":-5.344255,"median":-1.965361,"eighty":-1.010992,"marketCap":469033219},{"date":"2026-02-06","current":-2.579827,"twenty":-5.065967,"median":-1.978384,"eighty":-1.01346,"marketCap":415331486},{"date":"2026-02-13","current":-2.611764,"twenty":-5.054609,"median":-2.003915,"eighty":-1.013717,"marketCap":420473142},{"date":"2026-02-20","current":-2.87436,"twenty":-4.986457,"median":-2.025703,"eighty":-1.014247,"marketCap":462748974}],"updateTime":1771693719586},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KYTX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610969273","title":"Kyverna Therapeutics Files Initial Beneficial Ownership Statement for Chief Technology Officer Mayobanex Pujols","url":"https://stock-news.laohu8.com/highlight/detail?id=2610969273","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610969273?lang=en_us&edition=fundamental","pubTime":"2026-02-12 05:31","pubTimestamp":1770845481,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Mayobanex Pujols as the beneficial owner, serving as the company’s Chief Technology Officer. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 11, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDL8k0bbk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Kyverna Therapeutics Files Initial Beneficial Ownership Statement for Chief Technology Officer Mayobanex Pujols","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"gpt_icon":0},{"id":"2608587988","title":"Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2608587988","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608587988?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:00","pubTimestamp":1770123637,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics Inc. has appointed Mayo Pujols as Chief Technology Officer, effective February 9, 2026. Mr. Pujols brings over 30 years of experience in technical operations, particularly in commercial manufacturing for CAR T-cell therapies and biologics, as the company prepares for the potential launch of miv-cel for stiff person syndrome.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 03, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDLV0t8M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","SG9999014005.SGD","SG9999014013.SGD","BK4112","IE00BGHQF748.EUR","SG9999014021.USD","IE00B64PRP62.GBP","NDAQ","KYTX","LU2210149790.SGD","LU2210150020.SGD","BK4139","LU2095319765.USD","IE00B3QW5Z07.USD","SG9999014039.USD","BK4585","BK4588","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2603466166","title":"Kyverna Therapeutics Showcases Breakthrough CAR T Results in Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2603466166","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603466166?lang=en_us&edition=fundamental","pubTime":"2026-01-15 02:09","pubTimestamp":1768414143,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics Inc. presented new clinical data highlighting the performance of its CAR T cell therapy, Miv-cel , in patients with stiff person syndrome . The company reported statistically significant improvements across all primary and secondary endpoints in the KYSA-8 registrational trial, including the Timed 25-Foot Walk, Modified Rankin Scale, Distribution of Stiffness Index, Hauser Ambulation Index, and Heightened Sensitivity Scale. The therapy demonstrated a 100% elimination of off-label immunotherapies with a single dose and was described as well-tolerated with a manageable safety profile. The trial results establish a clear regulatory path for a Biologics License Application filing in the first half of 2026, with the company positioned to be first-to-market in SPS and plans to follow with myasthenia gravis. Kyverna also noted strengthened financial resources with a cash runway into 2028. You can access the full presentation through the link below.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL8RN1bk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"gpt_icon":0},{"id":"2603552473","title":"Kyverna Therapeutics: Strong Early Autoimmune CAR-T Data, Accelerated SPS Timeline, and Solid Cash Runway Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2603552473","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603552473?lang=en_us&edition=fundamental","pubTime":"2026-01-13 07:05","pubTimestamp":1768259118,"startTime":"0","endTime":"0","summary":"William Blair analyst Sami Corwin has maintained their bullish stance on KYTX stock, giving a Buy rating today. Sami Corwin has given his Buy ratin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/kyverna-therapeutics-strong-early-autoimmune-car-t-data-accelerated-sps-timeline-and-solid-cash-runway-support-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/kyverna-therapeutics-strong-early-autoimmune-car-t-data-accelerated-sps-timeline-and-solid-cash-runway-support-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYTX","CAR"],"gpt_icon":0},{"id":"2602548284","title":"Kyverna Therapeutics provides corporate update, priorities for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602548284","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602548284?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:38","pubTimestamp":1768225136,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics (KYTX) provided a corporate update and outlined its strategic priorities for 2026. Highlights include: Advancing valuable comm...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kyverna-therapeutics-provides-corporate-update-priorities-for-2026-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kyverna-therapeutics-provides-corporate-update-priorities-for-2026-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KYTX"],"gpt_icon":0},{"id":"2602551022","title":"Kyverna Therapeutics Inc - Appoints Christi Shaw as Executive Chairperson - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2602551022","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602551022?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:17","pubTimestamp":1768223820,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD16D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2602551704","title":"BRIEF-Kyverna Therapeutics Provides Corporate Update And Outlines 2026 Strategic Priorities At The J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2602551704","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602551704?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222842,"startTime":"0","endTime":"0","summary":"BRIEF-Kyverna Therapeutics Provides Corporate Update And Outlines 2026 Strategic Priorities At The J.P. Morgan Healthcare ConferenceJan 12 (Reuters) - Kyverna Therapeutics Inc KYTX.O:KYVERNA THERAPEUT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA1CTXBL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2602170075","title":"Kyverna Therapeutics Names Christi Shaw Executive Chairperson","url":"https://stock-news.laohu8.com/highlight/detail?id=2602170075","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602170075?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222840,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics Inc. has appointed Christi Shaw as Executive Chairperson of its Board, enhancing the company's expertise in CAR T-cell therapy commercialization. Ian Clark, the former Chairperson, will remain on the Board as a Director.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL5M6WYX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","KYTX","SG9999014013.SGD","LU2210149790.SGD","SG9999014021.USD","BK4585","LU2210150020.SGD","BK4139","IE00BKPKM429.USD","SG9999014039.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0314104364.USD","NDAQ","BK4112","SG9999014005.SGD","LU2095319765.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2602851003","title":"Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2602851003","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602851003?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222800,"startTime":"0","endTime":"0","summary":"Advancing valuable commercial opportunity in stiff person syndrome (SPS) following landmark registrational data; Biologics License Application (BLA) submission anticipated in 1H 2026  First patient en","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/12/3216812/0/en/Kyverna-Therapeutics-Provides-Corporate-Update-and-Outlines-2026-Strategic-Priorities-at-the-J-P-Morgan-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2133065610.SGD","LU1244550494.USD","LU0098860793.USD","LU0557290698.USD","LU1791710582.SGD","LU2111349929.HKD","LU2357305700.SGD","LU0128526141.USD","BK4581","LU1244550577.SGD","LU1989772840.SGD","LU0234570918.USD","LD","BK4137","LU2089284900.SGD","IND","BK4504","LU0795875169.SGD","XBI","BK4585","LU0267386448.USD","BK4534","LU0225283273.USD","LU0006306889.USD","LU2271345857.HKD","LU0320765646.SGD","LABU","LU1791710400.SGD","BK4588","LU0029874061.USD","LU1989772923.USD","LU2089283258.USD","LU0882574139.USD","LU1732799900.SGD","CAR","LU0528227936.USD","LU0795875086.SGD","LU1720051017.SGD","XLV","LU1162221912.USD","HCSG","LU1732800096.USD","LU0106831901.USD","LU1668664300.SGD","LU0314104364.USD","LU0912757837.SGD","KYTX","LU1548497426.USD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2601881630","title":"Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2601881630","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601881630?lang=en_us&edition=fundamental","pubTime":"2026-01-05 21:00","pubTimestamp":1767618000,"startTime":"0","endTime":"0","summary":"EMERYVILLE, Calif., Jan.  05, 2026  (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/05/3212695/0/en/Kyverna-Therapeutics-to-Present-at-the-J-P-Morgan-2026-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0267386448.USD","LU1363072403.SGD","LU1989772923.USD","LU0795875086.SGD","LU1791710582.SGD","BK4127","LU0314104364.USD","BK4581","LU1791710400.SGD","KYTX","LU0158827948.USD","XLV","LU1720051108.HKD","LU2357305700.SGD","LU0528227936.USD","LU2089284900.SGD","LU1162221912.USD","LU0098860793.USD","BK4139","LU0106831901.USD","BK4534","LU1732799900.SGD","LU0106261372.USD","LU2347655156.SGD","LU0234570918.USD","LU1074936037.SGD","LU0882574139.USD","IE00BZ1G4Q59.USD","LU0795875169.SGD","LU1244550577.SGD","LU2111349929.HKD","BK4585","LU1732800096.USD","HCSG","LU1244550221.USD","LU0029874061.USD","LU1548497426.USD","XBI","BK4137","BK4516","LU0320765646.SGD","BK4588","LU0912757837.SGD","LU2133065610.SGD","LU1668664300.SGD","LU2028103732.USD","LABU","LU0158827781.USD","IE00BKVL7J92.USD","LU2271345857.HKD"],"gpt_icon":0},{"id":"2593431323","title":"Director Beth C. Seidenberg Acquires Common Shares of Kyverna Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2593431323","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593431323?lang=en_us&edition=fundamental","pubTime":"2025-12-23 00:44","pubTimestamp":1766421856,"startTime":"0","endTime":"0","summary":"Beth C. Seidenberg, Director, has reported the acquisition of common shares of Kyverna Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 22, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDLc4TpDL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"gpt_icon":0},{"id":"2593743131","title":"Westlake BioPartners Opportunity Fund I, L.P. Reports Acquisition of Kyverna Therapeutics Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2593743131","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593743131?lang=en_us&edition=fundamental","pubTime":"2025-12-23 00:43","pubTimestamp":1766421798,"startTime":"0","endTime":"0","summary":"Westlake BioPartners Opportunity Fund I, L.P. has reported the acquisition of common shares of Kyverna Therapeutics Inc. , according to a recent SEC filing. The Form 4 was filed by more than one reporting person, including Westlake BioPartners Opportunity Fund I, L.P. and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 22, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL9S5sH9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Westlake BioPartners Opportunity Fund I, L.P. Reports Acquisition of Kyverna Therapeutics Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"gpt_icon":0},{"id":"2592409669","title":"Kyverna Therapeutics Chief Technology Officer Karen Marie Walker Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592409669","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592409669?lang=en_us&edition=fundamental","pubTime":"2025-12-18 09:30","pubTimestamp":1766021444,"startTime":"0","endTime":"0","summary":"Karen Marie Walker, Chief Technology Officer of Kyverna Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 17, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL57Kqwq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kyverna Therapeutics Chief Technology Officer Karen Marie Walker Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"gpt_icon":0},{"id":"2592911237","title":"Kyverna Therapeutics Down Over 29%, On Track for Largest Percent Decrease Since June 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2592911237","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592911237?lang=en_us&edition=fundamental","pubTime":"2025-12-18 00:06","pubTimestamp":1765987560,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics, Inc.  is currently at $7.19, down $3.05 or 29.79%. --Would be lowest close since Dec. 3, 2025, when it closed at $7.18. --On pace for largest percent decrease since June 14, 2024, when it fell 34%. --Currently down two consecutive days; down 33.55% over this period. --Up 92.25% year-to-date; on pace for best year on record . --Down 76.11% from its all-time closing high of $30.10 on Feb. 9, 2024. --Up 89.71% from 52 weeks ago , when it closed at $3.79. --Down 33.55% from its 52-week closing high of $10.82 on Dec. 15, 2025. --Up 292.9% from its 52-week closing low of $1.83 on April 16, 2025. --Traded as low as $6.72; lowest intraday level since Dec. 3, 2025, when it hit $6.53. --Down 34.38% at today's intraday low; largest intraday percent decrease since June 14, 2024, when it fell as much as 39.06%","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2592091186","title":"BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Robinhood Markets, Cannabis stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2592091186","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592091186?lang=en_us&edition=fundamental","pubTime":"2025-12-17 23:40","pubTimestamp":1765986030,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Robinhood Markets, Cannabis stocksEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call ne","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nL6N3XN14O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HL","NFE","AVTR","FDX","SPOT","CVS","CVX","HOOD","VOR","WSBC","NWBI","IMNM","GIS","VERU","MCK","PSKY","SCCO","COR","NUE","DHR","ALB","COP","APOG","ABM","WAT","FISI","WMB","NEM","TXRH","CNX","XENE","JBL","KYMR","HUT","FCF","CYTK","KYTX","LNG","PANW","NEO","TPL","VSCO","FTNT","FCX","COUR","XOM"],"gpt_icon":1},{"id":"2592915170","title":"Kyverna Therapeutics Inc - Underwriters Granted Option for 1,999,999 Additional Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592915170","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592915170?lang=en_us&edition=fundamental","pubTime":"2025-12-17 22:24","pubTimestamp":1765981472,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA3BQPNT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2592791517","title":"Kyverna Therapeutics Inc - Prices Public Offering of 13,333,333 Shares of Common Stock at $7.50 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2592791517","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592791517?lang=en_us&edition=fundamental","pubTime":"2025-12-17 22:24","pubTimestamp":1765981472,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA3BQPNT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYTX"],"gpt_icon":0},{"id":"2592478915","title":"Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2592478915","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592478915?lang=en_us&edition=fundamental","pubTime":"2025-12-17 22:24","pubTimestamp":1765981440,"startTime":"0","endTime":"0","summary":"EMERYVILLE, Calif., Dec.  17, 2025  (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna”), a clinical-stage biopharmaceutical company focused on developing cell therapies for patie","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/17/3207060/0/en/Kyverna-Therapeutics-Announces-Pricing-of-100-Million-Public-Offering-of-Common-Stock.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0557290698.USD","LU0795875169.SGD","LU1791710582.SGD","LU0971096721.USD","LU2089283258.USD","BK4585","BK4516","LU1732799900.SGD","BK4127","LU2111349929.HKD","BK4534","LU0225283273.USD","BK4139","LU0795875086.SGD","LU1989772923.USD","LU0106831901.USD","LU1162221912.USD","LU2347655156.SGD","LU1720051017.SGD","LU1791710400.SGD","LU1244550494.USD","LU2133065610.SGD","LU1720051108.HKD","LU0098860793.USD","LU1244550221.USD","LU2023251221.USD","LU0158827781.USD","IE00BZ1G4Q59.USD","LU0158827948.USD","LU0234570918.USD","LU0882574139.USD","LU1548497426.USD","LU1363072403.SGD","LU1989772840.SGD","LU2271345857.HKD","LU0320765646.SGD","LU1244550577.SGD","LU0106261372.USD","LU0528227936.USD","LU1668664300.SGD","KYTX","LU0267386448.USD","BK4588","IE00BKVL7J92.USD","LU2028103732.USD","LU0912757837.SGD","LU1732800096.USD","LU2357305700.SGD","LU1074936037.SGD","LU0006306889.USD"],"gpt_icon":0},{"id":"2592902059","title":"Investors Parse Jobs Data, Look Ahead to Inflation Report as US Futures Rise Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2592902059","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592902059?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:12","pubTimestamp":1765977126,"startTime":"0","endTime":"0","summary":"US stock futures are tracking higher in Wednesday's premarket session as investors dissect Tuesday's employment reports, and look ahead to Thursday's inflation reading for November.The Dow Jones Indus","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"2383074a52c258f664e165501a1e7f86","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AMCI","BK4023","KYTX","AZI.AU","BK4595","ISBC","BK4094","BK4600","BK4139","BK4211","HUT","BK7095","BK4214","PLCE","AZI","DBVT"],"gpt_icon":1},{"id":"2591935933","title":"Kyverna Therapeutics Is Maintained at Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2591935933","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591935933?lang=en_us&edition=fundamental","pubTime":"2025-12-16 23:06","pubTimestamp":1765897560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KYTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 16, 2025 10:06 ET (15:06 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":82,"code":"91000000","status":"200"}]}}